Complete Response Letters: US FDA Trying To Identify Subsets For Public Release
Agency want to identify a 'manageable' subset of letters for release in which drug approval was denied for reasons, such as safety concerns, that can help inform clinical practice and impact public health, Commissioner Gottlieb says, adding: 'I'm not sure that that's doable. I'm inclined to think that it might be.'
You may also be interested in...
US FDA’s Califf Says Publishing Complete Response Letters Could Help Fight Misinformation
But the commissioner also said proponents of releasing CRs may be making too much of the idea, because there are few CRs actually issued.
Complete Response Letters: Industry Prefers Communication Before Rather Than Docs After
Rep. Dunn’s idea would be a return to prior agency practice; the documents are currently considered exempt from disclosure.
Complete Response Letters: US FDA Tells Congress Broader Disclosures To Sponsors Could Be ‘Chilling’
A lengthy hearing that addressed everything from Aduhelm to advanced manufacturing serves as the formal kick off of the user fee reauthorization season and offers a preview of many possible FDA reforms that House members could seek to include in the legislation.